(Q40190734)

18 September 2017

title

Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor (English)

1 reference

18 September 2017

1 reference

2

Tetsuo Takehara

1 reference

18 September 2017

1

Tomohide Tatsumi

1 reference

18 September 2017

Shinjiro Yamaguchi

3

1 reference

18 September 2017

Akira Sasakawa

4

1 reference

18 September 2017

Ryotaro Sakamori

5

1 reference

18 September 2017

Kazuyoshi Ohkawa

6

1 reference

18 September 2017

Keisuke Kohga

7

1 reference

18 September 2017

Akio Uemura

8

1 reference

18 September 2017

Norio Hayashi

9

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

45

1 reference

18 September 2017

issue

1

1 reference

18 September 2017

page(s)

22-30

1 reference

NK cell compartments and their activation by dendritic cells

18 September 2017

cites work

1 reference

NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells

21 January 2018

1 reference

The dendritic cell system and its role in immunogenicity

21 January 2018

1 reference

7 January 2021

Manipulating dendritic cell biology for the active immunotherapy of cancer

1 reference

7 January 2021

Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo

1 reference

7 January 2021

Reciprocal activating interaction between natural killer cells and dendritic cells

1 reference

7 January 2021

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells

1 reference

7 January 2021

Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells

1 reference

7 January 2021

Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity

1 reference

7 January 2021

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

1 reference

7 January 2021

Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells

1 reference

7 January 2021

The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells

1 reference

7 January 2021

Innate and adaptive lymphoid cells in the human liver

1 reference

7 January 2021

Immunology of the healthy liver: old questions and new insights

1 reference

7 January 2021

Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells

1 reference

7 January 2021

A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer

1 reference

7 January 2021

Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma

1 reference

7 January 2021

Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial

1 reference

7 January 2021

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

1 reference

7 January 2021

alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria

1 reference

7 January 2021

CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver

1 reference

7 January 2021

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

1 reference

7 January 2021

A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer

1 reference

7 January 2021

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

1 reference

7 January 2021

Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases.

1 reference

7 January 2021

Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines

1 reference

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

7 January 2021

Dendritic cell-based immunotherapy of prostate cancer

1 reference

7 January 2021

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

1 reference

7 January 2021

Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide

1 reference

7 January 2021

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

1 reference

7 January 2021

The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation

1 reference

7 January 2021

The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21447

1 reference

18 September 2017

1 reference